EYZANFY (ALT-L9, aflibercept, Eylea biosimilar) received marketing approval from the Ministry of Food and Drug Safety (MFDS) on May 14, 2026
The application was filed on September 12, 2024, and approval covers all four indications of the original Eylea (wet AMD, RVO-ME, DME, myopic CNV)
The company plans to launch domestically based on the approval, expecting import substitution and reduction in healthcare costs through lower drug prices
KOSDAQ Filing Information
Filing: Major Management Matters Related to Investment Decision (Eizenpju (ALT-L9, Ailia Biosimilar) MFDS Product Approval)